Navigation Links
Cellectricon Receives Milestone Order for Cellaxess(R)HT, the World's First High Throughput RNAi Screening System
Date:11/12/2008

GOTHENBURG, Sweden, November 12 /PRNewswire/ -- Cellectricon, a leading provider of advanced screening solutions for drug discovery, has today received its most significant and largest single order to date. The order includes three Cellaxess(R)HT systems and the customer is a leading US biotech firm.

"An order of this magnitude proves the system's unique features and value, and validates Cellectricon's strategy to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations." says Jonas Ohlsson, CEO at Cellectricon. "Cellectricon has developed the Cellaxess(R)HT system in close collaboration with leading pharmaceutical companies and academic research groups to meet the rapidly growing demand for a true high throughput transfection screening technology, capable of reagent-free delivery of genetic material to biologically relevant cell types."

Cellaxess(R)HT is the world's first fully automated workstation for high throughput RNAi screening on biologically relevant cell types. The system enables reagent free delivery of siRNA and cDNA to a wide range of primary cells and cell lines with excellent efficiency and viability at a throughput of 50, 000 wells per day. Cellaxess(R)HT is first of its kind on the market and will significantly impact target discovery by providing key functional data in relevant primary human cells.

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology market. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

Contact Details:

Jonas Ohlsson, CEO

Phone: +46(0)709-73-47-92

E-mail: jonas.ohlsson@cellectricon.com

Susanne Fagerlund

VP Marketing & Communications

Phone: +46(0)31-760-35-15

E-mail: susanne.fagerlund@cellectricon.com


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
2. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
3. China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
4. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
5. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
6. Valor Medical Closes $1.4 Million Convertible Debt and Receives ISO 13485 Certification
7. Aposense Receives Frost & Sullivan Technology Innovation of the Year Award
8. Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital
9. Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter
10. Environmental Tectonics Corporations Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/21/2016)... June 21, 2016 NuData Security announced today ... role of principal product architect and that ... of customer development. Both will report directly to ... The moves reflect NuData,s strategic growth in its ... high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
Breaking Biology News(10 mins):